Julia Belluz

@juliaoftoronto · Paris, France · joined 20 Sep 2009

Health journalist, contributing opinion writer @nytimes. Formerly @voxdotcom, @MIT Knight Fellow etc. juliabelluz@bsky.social Book: https://t.co/F0UrpthF3C

33 489Followers

2 908Following

17 468Posts total

68.5KViews on collected posts

Against accounts of the same size

3 posts from the last 90 days, next to the 10K–100K follower range. shown widely, but few of those viewers react.

Median views8 077this account3 383median for 10K–100K

Reach, %24.12%this account10.96%median for 10K–100K

Engagement, %0.43%this account1.40%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	8 077	3 383	2.39×
Reach (views ÷ followers)	24.12%	10.96%	2.20×
Engagement rate	0.43%	1.40%	0.31×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

4.8K6 May

3.9K8 May

1.2K24 Jul

50.5K25 Jul

8.1K27 Jul

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.23%6 May

1.09%8 May

1.02%24 Jul

0.17%25 Jul

0.43%27 Jul

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.40%.

What the audience does

Likes47.4%111 in total

Reposts11.5%27 in total

Replies13.2%31 in total

Quotes6.8%16 in total

Bookmarks20.9%49 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

For decades, ppl have talked about the toxic food environment and how it’s stacked against most people. For decades, little’s changed policy-wise. I increasingly think there’s only one way out. That way is litigation. https://t.co/pXtFw01PVG @nytopinion 8.1K views · 21 likes · 7 reposts · 3 replies 27 Jul 2026 Americans want to inject unproven chemicals. They may soon get their way. An FDA advisory meeting voted to make it easier to access six experimental #peptides. But the meeting was never just about peptides. I wrote about why for @nytopinion https://t.co/NjI5yyKMLz 50.5K views · 40 likes · 17 reposts · 18 replies 25 Jul 2026 Until #GLP1s, there's never been a drug states have so completely lost control over. I spoke to Apple News In Conversation about what this tells us about our health system, how it needs to change, and more. You can listen here. https://t.co/ZqRRFOuNDO https://t.co/Jm9bfjVUWv 1.2K views · 10 likes · 0 reposts · 1 replies 24 Jul 2026 #GLP1s like #Ozempic come as close to wonder drugs as perhaps we've ever had. They're also meeting a really weird moment: the wellness and appearance obsessed algorithmic age @ezraklein and I talked about these two things colliding. Weirdness ensues. https://t.co/LxUZxWnlIM ht 3.9K views · 35 likes · 1 reposts · 7 replies 08 May 2026 A few years back, the @AmerAcadPeds recommended more intensive medical intervention for kids with obesity, including GLP-1s. T he question now is not whether we should give these drugs to kids. It's: why are we even here? My latest @nytopinion https://t.co/qPQcCrdf8M 4.8K views · 5 likes · 2 reposts · 2 replies 06 May 2026